245 related articles for article (PubMed ID: 12709777)
21. Fear-potentiated startle and light-enhanced startle models in drug discovery.
Groenink L; Bijlsma EY; Olivier B
Curr Protoc Pharmacol; 2008 Jun; Chapter 5():Unit5.48. PubMed ID: 22294228
[TBL] [Abstract][Full Text] [Related]
22. Diazepam blocks fear-potentiated startle in humans.
Patrick CJ; Berthot BD; Moore JD
J Abnorm Psychol; 1996 Feb; 105(1):89-96. PubMed ID: 8666715
[TBL] [Abstract][Full Text] [Related]
23. Fear-potentiated startle response is remarkably similar in two laboratories.
Joordens RJ; Hijzen TH; Peeters BW; Olivier B
Psychopharmacology (Berl); 1996 Jul; 126(2):104-9. PubMed ID: 8856828
[TBL] [Abstract][Full Text] [Related]
24. The contribution of contextual fear in the anxiolytic effect of chlordiazepoxide in the fear-potentiated startle test.
Zhao Y; Bijlsma EY; Verdouw PM; Garssen J; Groenink L
Behav Brain Res; 2018 Nov; 353():57-61. PubMed ID: 29969605
[TBL] [Abstract][Full Text] [Related]
25. Effects of the group II metabotropic glutamate receptor agonist, LY354740 on schedule-controlled behaviour in rats.
Moore NA; Rees G; Monn JA
Behav Pharmacol; 1999 May; 10(3):319-25. PubMed ID: 10780246
[TBL] [Abstract][Full Text] [Related]
26. Group II mGluR agonist LY354740 and NAAG peptidase inhibitor effects on prepulse inhibition in PCP and D-amphetamine models of schizophrenia.
Profaci CP; Krolikowski KA; Olszewski RT; Neale JH
Psychopharmacology (Berl); 2011 Jul; 216(2):235-43. PubMed ID: 21327758
[TBL] [Abstract][Full Text] [Related]
27. Effects of threat of shock, shock electrode placement and darkness on startle.
Grillon C; Ameli R
Int J Psychophysiol; 1998 May; 28(3):223-31. PubMed ID: 9545658
[TBL] [Abstract][Full Text] [Related]
28. Control conditions in the fear-potentiated startle response paradigm.
Joordens RJ; Hijzen TH; Peeters BW; Olivier B
Neuroreport; 1997 Mar; 8(4):1031-4. PubMed ID: 9141086
[TBL] [Abstract][Full Text] [Related]
29. Effects of the mGluR2/3 agonist LY354740 on computerized tasks of attention and working memory in marmoset monkeys.
Spinelli S; Ballard T; Gatti-McArthur S; Richards GJ; Kapps M; Woltering T; Wichmann J; Stadler H; Feldon J; Pryce CR
Psychopharmacology (Berl); 2005 Apr; 179(1):292-302. PubMed ID: 15678362
[TBL] [Abstract][Full Text] [Related]
30. Comparison of the mGlu(5) receptor positive allosteric modulator ADX47273 and the mGlu(2/3) receptor agonist LY354740 in tests for antipsychotic-like activity.
Schlumberger C; Pietraszek M; Gravius A; Klein KU; Greco S; Morè L; Danysz W
Eur J Pharmacol; 2009 Nov; 623(1-3):73-83. PubMed ID: 19765575
[TBL] [Abstract][Full Text] [Related]
31. Infusion of flesinoxan into the amygdala blocks the fear-potentiated startle.
Groenink L; Joordens RJ; Hijzen TH; Dirks A; Olivier B
Neuroreport; 2000 Jul; 11(10):2285-8. PubMed ID: 10923686
[TBL] [Abstract][Full Text] [Related]
32. Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039).
Rorick-Kehn LM; Johnson BG; Burkey JL; Wright RA; Calligaro DO; Marek GJ; Nisenbaum ES; Catlow JT; Kingston AE; Giera DD; Herin MF; Monn JA; McKinzie DL; Schoepp DD
J Pharmacol Exp Ther; 2007 Apr; 321(1):308-17. PubMed ID: 17204749
[TBL] [Abstract][Full Text] [Related]
33. LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress.
Schoepp DD; Wright RA; Levine LR; Gaydos B; Potter WZ
Stress; 2003 Sep; 6(3):189-97. PubMed ID: 13129812
[TBL] [Abstract][Full Text] [Related]
34. LY354740: a metabotropic glutamate receptor agonist which ameliorates symptoms of nicotine withdrawal in rats.
Helton DR; Tizzano JP; Monn JA; Schoepp DD; Kallman MJ
Neuropharmacology; 1997; 36(11-12):1511-6. PubMed ID: 9517421
[TBL] [Abstract][Full Text] [Related]
35. The benzodiazepine alprazolam dissociates contextual fear from cued fear in humans as assessed by fear-potentiated startle.
Grillon C; Baas JM; Pine DS; Lissek S; Lawley M; Ellis V; Levine J
Biol Psychiatry; 2006 Oct; 60(7):760-6. PubMed ID: 16631127
[TBL] [Abstract][Full Text] [Related]
36. The CRH1 antagonist GSK561679 increases human fear but not anxiety as assessed by startle.
Grillon C; Hale E; Lieberman L; Davis A; Pine DS; Ernst M
Neuropsychopharmacology; 2015 Mar; 40(5):1064-71. PubMed ID: 25430779
[TBL] [Abstract][Full Text] [Related]
37. GABA-A and 5-HT1A receptor agonists block expression of fear-potentiated startle in mice.
Risbrough VB; Brodkin JD; Geyer MA
Neuropsychopharmacology; 2003 Apr; 28(4):654-63. PubMed ID: 12655310
[TBL] [Abstract][Full Text] [Related]
38. Anxiolytic-like effects of the neurokinin 1 receptor antagonist GR-205171 in the elevated plus maze and contextual fear-potentiated startle model of anxiety in gerbils.
Heldt SA; Davis M; Ratti E; Corsi M; Trist D; Ressler KJ
Behav Pharmacol; 2009 Oct; 20(7):584-95. PubMed ID: 19675456
[TBL] [Abstract][Full Text] [Related]
39. Roles of group II metabotropic glutamate receptors in modulation of seizure activity.
Kłodzińska A; Bijak M; Chojnacka-Wójcik E; Kroczka B; Swiader M; Czuczwar SJ; Pilc A
Naunyn Schmiedebergs Arch Pharmacol; 2000 Mar; 361(3):283-8. PubMed ID: 10731041
[TBL] [Abstract][Full Text] [Related]
40. Acute hydrocortisone treatment increases anxiety but not fear in healthy volunteers: a fear-potentiated startle study.
Grillon C; Heller R; Hirschhorn E; Kling MA; Pine DS; Schulkin J; Vythilingam M
Biol Psychiatry; 2011 Mar; 69(6):549-55. PubMed ID: 21277566
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
